Article

Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis.

Hematology Service, University Hospital of Salamanca; and Centro de Investigación del Cancer (CIC), University of Salamanca, CSIC, Spain.
Bone Marrow Transplantation (impact factor: 3.75). 02/2000; 25(2):217-8. DOI:10.1038/sj.bmt.1702102 pp.217-8
Source: PubMed

ABSTRACT Patients with hypereosinophilic syndrome (HES) display a very heterogeneous clinical picture ranging from asymptomatic cases to very aggressive forms. We report a 38-year-old woman with progressive HES who developed severe myelofibrosis and was treated by allogeneic stem cell transplantation, using peripheral blood (PBSCT) instead of bone marrow as the source of progenitor cells, after conditioning with cytoxan and busulphan. To the best of our knowledge, this is the first case of HES with myelofibrosis treated with PBSCT. The patient remains alive 8 months post-PBSCT, and bone marrow fibrosis has significantly decreased following transplantation. Bone Marrow Transplantation (2000) 25, 217-218.

0 0
 · 
0 Bookmarks
 · 
15 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

38-year-old woman
 
alive 8 months post-PBSCT
 
asymptomatic cases
 
bone marrow
 
bone marrow fibrosis
 
Bone Marrow Transplantation
 
cell transplantation
 
conditioning
 
first case
 
HES
 
heterogeneous clinical picture
 
hypereosinophilic syndrome
 
Patients
 
progenitor cells
 
progressive HES
 

L Vazquez